

Case finding of dry eye disease in Norwegian optometric practice: a cross-sectional study

Ann Elisabeth Ystenæs*, Ingeborg Sand, and Vibeke Sundling

National Centre for Optics, Vision and Eye Care; Department of Optometry, Radiography and Lighting Design, Faculty of Health and Social Sciences, University of South-Eastern Norway, Kongsberg, Norway

Received November 26, 2020, accepted April 28, 2021.

* Correspondence: ann.elisabeth.ystenas@usn.no

Abstract

Optometrists are primary eye care providers, and it is essential that they efficiently identify patients who will benefit from dry eye management. The aim of the study was to explore case finding of dry eye disease (DED) in optometric practice.

A cross-sectional study examining dry eye symptoms and signs in 186 patients (18–70 years of age) attending a routine eye examination, with DED defined according to the criteria of the Tear Film and Ocular Surface Society Dry Eye Workshop II. Standard statistical tests were used, and clinical diagnostics were explored using sensitivity, specificity, and receiver-operating curve (ROC) statistics.

Fifty-six patients were contact lens wearers, and they were significantly younger than the non-contact lens wearers (mean age 35 ($SD = 1$) versus 48 (± 2) years). The mean best corrected visual acuity (BCVA) in the better eye was 1.0 (± 0.1) (decimal acuity). There was no difference in BCVA between contact lens wearers and non-contact lens wearers. The mean Ocular Surface Disease Index (OSDI) score was 22 (± 19), and 138 patients had at least one positive homeostasis marker. Eighty-six had DED, 52 had signs without symptoms, and 23 had symptoms without signs of DED. The sensitivity and specificity of OSDI in detecting any positive homeostasis marker were 62% and 54%, respectively. In all, 106 patients had meibomian gland dysfunction (MGD), of which 49 were asymptomatic. In a ROC analysis, an OSDI ≥ 13 showed a diagnostic ability to differentiate between patients with a fluorescein breakup time (FBUT) < 10 seconds and a fluorescein breakup time ≥ 10 seconds, but not between patients with and without staining or MGD.

The majority of patients had dry eye signs and/or dry eye symptoms. Routine assessment of FBUT and meibomian glands may enable case finding of DED in optometric practice.

Keywords: dry eye disease, Ocular Surface Disease Index, meibomian gland dysfunction, tear breakup time, ocular staining

Introduction

The Tear Film and Ocular Surface Society Dry Eye Workshop II (TFOS DEWS II) defines dry eye disease (DED) as “a multifactorial disease of the ocular surface characterized by a loss of homeostasis of the tear film, and accompanied by ocular symptoms, in which tear film instability and hyperosmolarity, ocular surface inflammation and damage, and neurosensory abnormalities play etiological roles” (Craig et al., 2017). The prevalence of DED varies from 5% to 50%, depending on the study population and diagnostic criteria, and is higher among females, in older age groups, and among people of Asian ethnicity (Stapleton et al., 2017). DED is associated with ocular pain and irritation, blurred vision, and anxiety and depression, and may limit daily activities and reduce work effectiveness and quality of life. Consequently, DED has significant socioeconomic implications

(Li et al., 2012; Stapleton et al., 2017; Uchino et al., 2014; Wan et al., 2016).

According to the TFOS DEWS II report, the diagnosis of dry eye should include assessment of both dry eye symptoms and tear film homeostasis markers (Wolffsohn et al., 2017). When DED is confirmed, further testing for sub-classification of DED and grading of severity is needed as treatment should be tailored to the type and severity of DED. Tests that differentiate evaporative dry eye (EDE) from aqueous deficient dry eye (ADDE) are essential as these conditions are managed differently (Jones et al., 2017).

Visual function is affected in DED, and decreased vision and transient blurring of vision are common complaints in DED patients (Ishida et al., 2005). Meibomian gland dysfunction (MGD) is the leading cause of EDE and associated ADDE. Among people with DED, 13% to 50% have MGD (Arita et al., 2019; Uchino et al., 2006; Viso et al., 2011). In people over 40 years of age, 38% to 68% have MGD, dependent on population and applied diagnostic criteria (Stapleton et al., 2017). Patients may have MGD without symptoms; these patients are often undiagnosed (Blackie et al., 2010). The TFOS International Workshop on Meibomian Gland Dysfunction (MGD report) suggests that meibomian gland expression should be part of routine examination in adults and that dry eye work-up should be undertaken in patients with MGD regardless of symptoms (Tomlinson et al., 2011).

Optometrists are primary eye care providers, and it is essential that they efficiently identify patients who will benefit from dry eye management. Studies report significant differences in examination of dry eye patients and a potential to enhance the identification of patients at risk of DED (Downie et al., 2013; Downie et al., 2016; van Tilborg et al., 2015), consequently indicating a need to improve and standardise the examination and diagnosis of DED in optometric practice. The aim of this study was to explore case finding of DED in general Norwegian optometric practice.

Methods

The study had a cross-sectional design. The study population was recruited from people attending for a routine eye examination by one dedicated optometrist in each of three Krogh Optikk practices in Trondheim and Oslo, Norway. To minimize observer bias, the optometrists followed written instructions on how to perform the dry eye examination, and standardised equipment was used for all patients. All patients aged 20 to 70 years attending for an eye examination or a contact lens fitting/follow-up during the period between 15th December 2015 and 1st February 2016 were invited to participate. All patients were given oral and written information and gave informed consent to take part in the study. Patients with other known ocular surface inflammations, previous trauma affecting the tear film examination, or known hypersensitivity to lissamine green and/or fluorescein were excluded from the study.

Data collection

The scheduled routine examination was undertaken, including patient history of contact lens wear, the use of systemic medication and computer screens, as well as decimal visual acuity at six metres equivalent distance. Further, a full dry eye examination was performed. The dry eye examination included the Ocular Surface Disease Index (OSDI) questionnaire, assessment of tear meniscus height (TMH), fluorescein tear breakup time (FBUT),

corneal and conjunctival staining, meibum expressibility, and meibum quality. The sequence of tear film tests was the same for all patients, starting with the least invasive tests first.

The participants started by answering the OSDI questionnaire. The OSDI questionnaire consists of 12 questions about symptoms, visual function, and environmental triggers, based on patients' experience of symptoms in the previous week. Each question was answered on a scale from 0 (none of the time) to 4 (all of the time). The total composite score (0–100) was calculated according to the formula of Schiffman et al. (2000). A normal ocular surface score is in the range of 0–12; a score of 13–22, 23–32, or 33–100 represents mild, moderate, or severe dry eye symptoms, respectively (Miller et al., 2010; Schiffman et al., 2000).

The tear meniscus height (TMH) was then examined with a slit lamp. The width of the slit was adjusted to be identical to the height of the tear meniscus, and the width of the slit in millimetres was recorded as the TMH. The fluorescein tear breakup time (FBUT) was measured by wetting a fluorescein strip with sterile saline solution and shaking off the excess saline; the strip was then carefully applied to the lower temporal conjunctiva starting with the right eye. There was one application of fluorescein in each eye, and no break between the examination of right eye and left eye. The FBUT time was observed using 10 times slit lamp magnification, cobalt blue light, and a yellow barrier filter. The patient was instructed to blink twice and then look straight ahead with their eyes open. The time in seconds from the last blink to the first dry spot appearing was measured by stopwatch and recorded. If the patient blinked before the tear film break was observed, the time to first blink was recorded. The measurement was repeated three times for each eye, and the mean value for each eye was calculated and recorded as the FBUT time. The FBUT for the worst eye was used for analysis.

For corneal and conjunctival staining, a strip impregnated with a mixture of 1.5 mg fluorescein and lissamine green was wetted with saline solution and applied to the lower temporal fornix. Corneal and conjunctival staining were observed using 16 times slit lamp magnification, using cobalt blue light with a yellow barrier filter, and white light, respectively. The staining was graded (0–5) according to the Oxford grading scheme (Bron et al., 2003).

Meibomian glands in the central part of the lower eyelid were examined for gland expressibility and meibum quality using digital pressure with cotton swabs for all participants. Five glands in the central part of the lower eyelid were graded (0–3) for expressibility: grade 0 when all glands were expressible, grade 1 when 3–4 glands were expressible, grade 2 when 1–2 glands were expressible, and grade 3 when no glands were expressible. The meibum quality of eight glands in the central part of the lower eyelid was graded from 0–3, giving a total score of 0–24. Grade 0 represented clear meibum fluid; grade 1, cloudy fluid; grade 2, cloudy fluid with debris; and grade 3, toothpaste-like meibum. MGD was defined as equivalent to stage 2 of the treatment algorithm for MGD, as either grade ≥ 1 for meibum expressibility or a sum score of ≥ 4 for meibum quality (Geerling et al., 2011; Nichols et al., n.d.; Tomlinson et al., 2011).

Definition and classification of dry eye disease and MGD

Dry eye disease was defined according to the recommendations of the TFOS DEWS II report (Wolffsohn et al., 2017). An OSDI score ≥ 13 was set as the criterion for dry eye symptoms. If, in addition, one or both homeostasis markers (FBUT and ocular surface staining) were positive, then DED was confirmed. A positive result for FBUT was defined as < 10 seconds. Positive ocular surface staining was defined as Oxford grade > 1 , which is equivalent to > 5 spots in the cornea or > 9 spots on the conjunctiva. TMH and meibomian gland function were used to

sub-classify dry eye disease as ADDE, EDE, a mix of both, or unclassifiable. ADDE was defined by a TMH < 0.2 mm and EDE by the presence of MGD.

Statistics

The data were analysed in frequency and summation tables. Group differences and associations were analysed with standard parametric and non-parametric statistical tests: chi-square, Student's *t*-test, and Spearman correlation. Clinical diagnostics were explored by the calculation of sensitivity and specificity and receiver operating curve (ROC) statistics. A *p*-value of < 0.05 was considered statistically significant.

Ethics

The research conformed to the Declaration of Helsinki, and the study was approved by the Regional Committee for Medical and Health Research Ethics (2015/2492).

Results

In all, 186 patients were examined, of which 118 (63%) were female. Their mean age was 44 years (± 15), ranging from 20 to 70 years. The mean age of females was 44 years (± 14), and the mean age of men was 45 years (± 15). Fifty-six patients (30%) were contact lens wearers; the contact lens wearers were significantly younger than non-contact lens wearers (mean age 35 (± 1) versus 48 (± 2) years), Student's *t*-test $p < 0.001$). All patients had normal vision; the mean best corrected decimal visual acuity (BCVA) in the better eye was 1.0 (± 0.1). BCVA was correlated with age ($r_s = -0.294$, $p < 0.001$). There was no difference in BCVA between contact lens wearers and non-lens wearers or between males and females.

The patients' mean OSDI score was 22 (± 19). The OSDI score was not associated with sex, age, contact lens wear, or BCVA. In all, 109 patients (58.6%) had dry eye symptoms; of these, 41 (37.6%), 26 (23.9%) and 42 (38.5%) had mild, moderate, and severe symptoms, respectively. In all, 138 patients (74.2%) had at least one positive homeostasis marker of DED (FBUT < 10 seconds and/or staining $>$ Oxford grade 1), of these 86 had dry eye symptoms (OSDI score ≥ 13) (see Table 1). Reduced FBUT and staining were not associated with sex, age, or contact lens wear.

Table 1: Signs of dry eye disease, MGD and reduced tear meniscus height in participants with and without dry eye symptoms, *n* (%).

| | All <i>n</i> =186 | Asymptomatic <i>n</i> =77 | Symptomatic <i>n</i> =109 |
|--|----------------------|------------------------------|------------------------------|
| FBUT < 10 seconds | 78 (41.9) | 26 (33.7) | 52 (47.7) |
| FBUT < 10 seconds and Staining $>$ Oxford grade 1 | 52 (28.0) | 21 (27.3) | 31 (28.4) |
| Staining $>$ Oxford grade 1 | 8 (4.3) | 5 (6.5) | 3 (2.8) |
| MGD | 72 (38.7) | 30 (38.9) | 42 (38.5) |
| MGD and TMH < 0.2 mm | 34 (18.3) | 19 (24.7) | 15 (13.7) |
| TMH < 0.2 mm | 27 (14.5) | 11 (14.3) | 16 (14.7) |

Note: FBUT = Fluorescein breakup time; MGD = Meibomian gland dysfunction; TMH = Tear meniscus height. Decimals rounded to nearest tenth.

In all, 106 (57.0%) patients had MGD, 49 (46.2%) of these were asymptomatic. Reduced TMH was found in 61 (32.8%) patients, of these 30 (49.2%) were asymptomatic. Among all patients, 34 (18.3%) had both MGD and reduced TMH (see Table 1). Among the symptomatic patients with MGD, MGD and reduced TMH, and reduced TMH, 6 (8.3%), 3 (8.8%) and 5 (18.5%), respectively, did not have positive homeostasis markers (dry eye signs). In all, 86 patients (46.2%) had DED (see Table 2). DED was not associated with sex, age, contact lens wear or BCVA. MGD and reduced TMH were not correlated with DED, sex or contact lens

wear. MGD, but not reduced TMH, was correlated with age ($r_s(186) = 0.255, p < 0.001$) (see Table 3). DED could be classified in 59 (68.6%) of the patients with DED (see Table 2). There was no statistically significant difference in the type of DED between males and females or between contact lens wearers and non-contact lens wearers.

Table 2: Prevalence and sub-classification of dry eye disease by sex, n (%).

| | All n=186 | Male n=68 | Female n=118 |
|---------------------|--------------|--------------|-----------------|
| Dry eye disease | 86 (46.2) | 26 (38.2) | 60 (50.8) |
| EDE | 36 (19.4) | 9 (13.2) | 27 (22.8) |
| Unclassifiable | 27 (14.5) | 9 (13.2) | 18 (15.3) |
| Mix of EDE and ADDE | 12 (6.5) | 2 (2.9) | 10 (8.5) |
| ADDE | 11 (5.9) | 6 (8.8) | 5 (4.2) |

Note: ADDE = Aqueous deficiency dry eye, EDE = Evaporative dry eye. Decimals rounded to nearest tenth.

Twenty-three patients (12.4%) had dry eye symptoms without dry eye signs, and 52 (28.0%) had dry eye signs without symptoms (see Figure 1). The sensitivity and specificity of OSDI in detecting any positive homeostasis marker were 62% and 54%, respectively. Table 4 shows the diagnostic accuracy of OSDI ≥ 13 in identifying people with positive homeostasis markers for DED and MGD. In a ROC analysis, OSDI ≥ 13 showed a diagnostic ability to discriminate between patients with fluorescein breakup time < 10 seconds and fluorescein breakup time ≥ 10 seconds, but not between patients with and without staining or MGD. The optimal cut-off value for the OSDI score was 10.41.


Table 3: Correlation between MGD and reduced TMH and age, gender, contact lens wear and DED.

| | Age | Gender | Contact lens wear | DED |
|-----|--------|--------|-------------------|--------|
| MDG | 0.255* | 0.062 | 0.005 | -0.022 |
| TMH | 0.045 | -0.040 | -0.062 | -0.120 |

Note: DED = Dry eye disease; MGD = Meibomian gland dysfunction; TMH = Tear meniscus height. *Statistically significant Spearman correlation $p < 0.001$.

Discussion

In this study, most participants had symptoms or signs of dry eye disease, and almost half had dry eye disease. The prevalence of DED is at the high end of the previously reported prevalence range (Stapleton et al., 2017). This may reflect the diagnostic criteria in our study. We defined DED based on symptoms and signs according to the guidelines of the TFOS DEWS II report (Wolffsohn et al., 2017). The definition of dry eye disease in previous studies varies in terms of cut-off values for symptoms and signs, as well as in study populations (Stapleton et al., 2017). Studies using both OSDI and signs report a prevalence of 8.7–10.7%; however, these studies applied a higher cut-off criterion for OSDI (≥ 23 and > 22), and one also applied a lower cut-off criterion for TBUT (Hashemi et al., 2014; Malet et al., 2014). This may explain the higher prevalence found in our study as the TFOS DEWS II also included patients with mild symptoms (OSDI score 13–22) in the diagnosis. Furthermore, the present study included patients attending for a routine eye examination, and they may therefore be more likely to have visual and ocular problems since they are seeking eye care. Nevertheless, our study illustrates the importance of dry eye assessment in optometric practice.



- Positive homeostasis maker – signs of dry eye
 - Negative homeostasis maker – no signs of dry eye
- Negative OSDI score (OSDI < 13)**
- Healthy eyes - no sign or symptoms of dry eye (true negative) – 14%
 - Predisposition to DED – signs of dry eye but no symptoms (false negative) – 28%
- Positive OSDI score (OSDI ≥ 13)**
- Pre-clinical DED – symptoms of dry eye but no signs (false positive) - 12%
 - DED – signs and symptoms of dry eye (true positive) - 46%

Figure 1: Distribution of participants with dry eye, pre-clinical dry eye, predisposition to dry eye and health eyes by OSDI-score and homeostasis markers.

Table 4: Diagnostic accuracy of OSDI ≥ 13 in identifying patients with dry eye signs and MGD.

| | Sensitivity | Specificity | AUC (95% CI) |
|---------------------------|-------------|-------------|------------------------|
| FBUT < 10 sec* | 64 | 54 | 0.590 (0.500 to 0.679) |
| Staining > Oxford grade 1 | 57 | 40 | 0.553 (0.460 to 0.646) |
| MGD | 54 | 35 | 0.503 (0.418 to 0.588) |

Note: AUC = area under curve; CI = confidence interval; FBUT = Fluorescein breakup time; MGD = Meibomian gland dysfunction; OSDI = Ocular surface disease index. *Statistical significance $p < 0.05$.

DED was not found to be associated with sex, age, or contact lens wear. These findings contradict other studies, which have shown increased prevalence of DED with increasing age (Farrand et al., 2017; Stapleton et al., 2017), a higher prevalence of DED in females than in males (Hashemi et al., 2014; Stapleton et al., 2017), and that DED is associated with contact lens wear (“The Epidemiology of Dry Eye Disease: Report of the Epidemiology Subcommittee of the International Dry Eye Workshop”, 2007). The lack of association between DED and sex, age, and contact lens wear in our study may reflect the inclusion of all stages of DED and the relatively young age of our participants. Moreover, age-related DED as well as contact lens complications in the younger contact lens wearers could mask differences between contact lens wearers and non-contact lens wearers. Previous studies have shown that differences between males and females become significant only in older age (Paulsen et al., 2014; Stapleton et al., 2017), and comparable studies have examined patients of higher age than in our study. Also, the lack of difference in DED between male and female could be due to the low sample size, and few men included in the study. Our findings may imply that case finding of dry eye disease in optometric practice is equally important in men and women, as well as in both contact lens wearers and non-contact lens wearers.

One in five participants with dry eye symptoms did not have findings of dry eye disease, and seven out of ten asymptomatic participants had findings of dry eye disease. This finding is supported by previous studies that have reported a lack of consis-

tency and low association between signs and symptoms in DED (Bartlett et al., 2015; Stapleton et al., 2017). This reflects the need for evidence-based guidelines in optometric practice including both symptoms and signs of DED to detect affected patients. By only using history and symptoms, including a questionnaire, some patients who might benefit from management of DED will likely continue to be undetected.

The OSDI score significantly differed between participants with and without reduced TBUT. This may reflect an unstable or irregular tear film, affecting optical quality and causing visual disturbance (Herbaut et al., 2019; Koh, 2018). However, there was no significant difference in BCVA between participants with and without DED. Nevertheless, vision may be affected even though visual acuity is normal, as an unstable tear film may cause higher order aberrations (Koh, 2018). Measurement of higher order aberrations was outside the scope of this study. Moreover, the association between TBUT and dry eye symptoms may also relate to dryness of the ocular surface caused by evaporation.

Reduced TBUT differentiated between participants with and without MGD, and MGD may cause both ocular discomfort and visual disturbance through a reduced function of the lipid layer, increasing tear evaporation and impeding the spread of the tear film over the ocular surface (Green-Church et al., 2011; Millar & Schuett, 2015). MGD may reduce lipid layer thickness and alter the lipid composition of the tear film, and previous studies report reduced TBUT in all subtypes of MGD (Xiao et al., 2020), as well as improved TBUT and reduced symptoms when MGD is treated (Kim et al., 2017; Lee et al., 2017). The unstable tear film caused by MGD may cause corneal exposure and staining, and in turn further destabilise the tear film (McMonnies, 2018), increasing tear evaporation and worsening the condition. Half of participants with MGD in our study had no symptoms. The MGD report suggests that dry eye work-up should be undertaken in patients with MGD regardless of symptoms (Tomlinson et al., 2011). This highlights the value of including TBUT as well as the assessment of meibomian gland function in routine eye examinations to detect DED. Almost half of the patients in the study had DED and required treatment to restore homeostasis. In addition, nearly one third were predisposed to DED, and one in ten had pre-clinical dry eye, which should also be considered for the preventive treatment of DED (Craig et al., 2017). This underlines the potential role of the optometrist in case finding, prevention, diagnosis, and management of DED.

Three out of ten cases of DED had normal TMH and normal meibomian gland function. This was not associated with contact lens wear, and the data were collected in winter, ruling out seasonal allergy and contact lens wear as likely explanations. Therefore, this may reflect other causes of staining and reduced TBUT, such as mucin deficiency and reduced blink rate and blink completeness (McMonnies, 2018) that also affect tear film stability. Mucin deficiency may contribute to increased tear evaporation (Willcox et al., 2017). Evaluation of blink rate, blink completeness, and evaluation of the mucin layer may provide further explanation of the underlying cause of DED.

The strength of this study is that it represents a true, real-life clinical setting. All the dry eye tests used are well-known, standardised tests available to optometrists without the need for additional expensive instrumentation. However, the lack of tear osmolarity in our test battery may have underestimated the prevalence of DED. The use of FBUT instead of NIBUT may have affected tear film stability and underestimated the frequency of reduced breakup time and consequently DED. Moreover, it would also be useful to include meibography to support the diagnosis of MGD.

In opposition to the discussed possible underestimation of DED, there could also be a selection bias in our study, overesti-

ating the prevalence of DED, as people having symptoms may be more eager to participate in the study than participants without symptoms. Our study was undertaken in 2015–2016, prior to the publication of the DEWS II report, hence this study did not include triaging questions that can differentiate DED from signs and symptoms of other causes (Wolffsohn et al., 2017). However, our analysis did not find any correlation between DED and risk factors like contact lens wear and medication use. Hence the prevalence of DED in our study likely represents true DED. The inclusion of three optometric practices and three different optometrists could also have introduced observer bias into the findings. However, written instructions for the dry eye assessment were given to the optometrists to ensure standardised examination and reduce bias.

Conclusion

In our study, the majority of patients had dry eye signs and/or dry eye symptoms. More than four out of five benefitted from management of dry eye and pre-clinical findings of dry eye, or advice on pre-disposition to dry eye. Screening with the OSDI questionnaire showed a low sensitivity and specificity in identifying patients with and without positive homeostasis markers. Including assessment of FBUT and meibomian glands in the routine eye examination may enhance case finding of patients with dry eye or those at risk of developing dry eye. The additional use of the OSDI questionnaire in patients with positive homeostasis markers will identify patients with DED or patients at risk of developing DED.

Acknowledgements

The authors thank the optometrists and patients collaborating in the data collection.

Conflicts of Interest

The authors declare no conflict of interest.

© Copyright Ystenæs, A. This article is distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use and redistribution provided that the original author and source are credited.

References

- Arita, R., Mizoguchi, T., Kawashima, M., Fukuoka, S., Koh, S., Shirakawa, R., Suzuki, T., & Morishige, N. (2019). Meibomian gland dysfunction and dry eye are similar but different based on a population-based study: The Hirado-Takushima Study in Japan. *American Journal of Ophthalmology*, 207, 410–418. <https://doi.org/10.1016/j.ajo.2019.02.024>
- Bartlett, J. D., Keith, M. S., Sudharshan, L., & Snedecor, S. J. (2015). Associations between signs and symptoms of dry eye disease: A systematic review. *Clinical Ophthalmology*, 9, 1719–30. <https://doi.org/10.2147/oph.S89700>
- Blackie, C. A., Korb, D. R., Knop, E., Bedi, R., Knop, N., & Holland, E. J. (2010). Nonobvious obstructive meibomian gland dysfunction. *Cornea*, 29(12), 1333–45. <https://doi.org/10.1097/ICO.0b013e3181d4f366>
- Bron, A. J., Evans, V. E., & Smith, J. A. (2003). Grading of corneal and conjunctival staining in the context of other dry eye tests. *Cornea*, 22(7), 640–50. <https://doi.org/10.1097/00003226-200310000-00008>
- Craig, J. P., Nichols, K. K., Akpek, E. K., Caffery, B., Dua, H. S., Joo, C. K., Liu, Z., Nelson, J. D., Nichols, J. J., Tsubota, K., & Stapleton, F. (2017). TFOS DEWS II Definition and classification report. *The Ocular Surface*, 15(3), 276–283. <https://doi.org/10.1016/j.jtos.2017.05.008>
- Downie, L. E., Keller, P. R., & Vingrys, A. J. (2013). An evidence-based analysis of Australian optometrists' dry eye practices. *Optometry and Vision Science*, 90(12), 1385–95. <https://doi.org/10.1097/OPX.0000000000000087>
- Downie, L. E., Rumney, N., Gad, A., Keller, P. R., Purslow, C., & Vingrys, A. J. (2016). Comparing self-reported optometric dry eye clinical practices in Australia and the United Kingdom: Is there scope for practice improvement? *Ophthalmic & Physiological Optics*, 36(2), 140–51. <https://doi.org/10.1111/opo.12280>
- Farrand, K. F., Fridman, M., Stillman, I. Ö., & Schaumberg, D. A. (2017). Prevalence of diagnosed dry eye disease in the United States among adults aged 18 years and older. *American Journal of Ophthalmology*, 182, 90–98. <https://doi.org/10.1016/j.ajo.2017.06.033>

- Geerling, G., Tauber, J., Baudouin, C., Goto, E., Matsumoto, Y., O'Brien, T., Rolando, M., Tsubota, K., & Nichols, K. K. (2011). The international workshop on meibomian gland dysfunction: Report of the subcommittee on management and treatment of meibomian gland dysfunction. *Investigative Ophthalmology & Visual Science*, 52(4), 2050–64. <https://doi.org/10.1167/iovs.10-6997g>
- Green-Church, K. B., Butovich, I., Willcox, M., Borchman, D., Paulsen, F., Barabino, S., & Glasgow, B. J. (2011). The international workshop on meibomian gland dysfunction: Report of the subcommittee on tear film lipids and lipid-protein interactions in health and disease. *Investigative Ophthalmology & Visual Science*, 52(4), 1979–93. <https://doi.org/10.1167/iovs.10-6997d>
- Hashemi, H., Khabazkhoob, M., Kheirkhah, A., Emamian, M. H., Mehravaran, S., Shariati, M., & Fotouhi, A. (2014). Prevalence of dry eye syndrome in an adult population. *Clinical and Experimental Ophthalmology*, 42(3), 242–8. <https://doi.org/10.1111/ceo.12183>
- Herbaut, A., Liang, H., Denoyer, A., Baudouin, C., & Labbé, A. (2019). Tear film analysis and evaluation of optical quality: A review of the literature. *Journal Français d'Ophtalmologie*, 42(2), e21–e35. <https://doi.org/https://doi.org/10.1016/j.jfo.2018.12.001>
- Ishida, R., Kojima, T., Dogru, M., Kaido, M., Matsumoto, Y., Tanaka, M., Goto, E., & Tsubota, K. (2005). The application of a new continuous functional visual acuity measurement system in dry eye syndromes. *American Journal of Ophthalmology*, 139(2), 253–8. <https://doi.org/10.1016/j.ajo.2004.08.075>
- Jones, L., Downie, L. E., Korb, D., Benitez-Del-Castillo, J. M., Dana, R., Deng, S. X., Dong, P. N., Geerling, G., Hida, R. Y., Liu, Y., Seo, K. Y., Tauber, J., Wakamatsu, T. H., Xu, J., Wolffsohn, J. S., & Craig, J. P. (2017). TFOS DEWS II Management and therapy report. *The Ocular Surface*, 15(3), 575–628. <https://doi.org/10.1016/j.jtos.2017.05.006>
- Kim, M. J., Stinnett, S. S., & Gupta, P. K. (2017). Effect of thermal pulsation treatment on tear film parameters in dry eye disease patients. *Clinical Ophthalmology*, 11, 883–886. <https://doi.org/10.2147/oph.S136203>
- Koh, S. (2018). Irregular astigmatism and higher-order aberrations in eyes with dry eye disease. *Investigative Ophthalmology & Visual Science*, 59(14), DES36–DES40. <https://doi.org/10.1167/iovs.17-23500>
- Lee, H., Kim, M., Park, S. Y., Kim, E. K., Seo, K. Y., & Kim, T. I. (2017). Mechanical meibomian gland squeezing combined with eyelid scrubs and warm compresses for the treatment of meibomian gland dysfunction. *Clinical and Experimental Ophthalmology*, 100(6), 598–602. <https://doi.org/10.1111/cxo.12532>
- Li, M., Gong, L., Chapin, W. J., & Zhu, M. (2012). Assessment of vision-related quality of life in dry eye patients. *Investigative Ophthalmology & Visual Science*, 53(9), 5722–7. <https://doi.org/10.1167/iovs.11-9094>
- Malet, F., Le Goff, M., Colin, J., Schweitzer, C., Delyfer, M.-N., Korobelnik, J.-F., Rougier, M.-B., Radeau, T., Dartigues, J.-F., & Delcourt, C. (2014). Dry eye disease in French elderly subjects: The Alienor Study. *Acta Ophthalmologica*, 92(6), e429–e436. <https://doi.org/10.1111/aos.12174>
- McMonnies, C. W. (2018). Tear instability importance, mechanisms, validity and reliability of assessment. *Journal of Optometry*, 11(4), 203–210. <https://doi.org/10.1016/j.optom.2017.11.004>
- Millar, T. J., & Schuett, B. S. (2015). The real reason for having a meibomian lipid layer covering the outer surface of the tear film – a review. *Experimental Eye Research*, 137, 125–138. <https://doi.org/https://doi.org/10.1016/j.exer.2015.05.002>
- Miller, K. L., Walt, J. G., Mink, D. R., Satram-Hoang, S., Wilson, S. E., Perry, H. D., Asbell, P. A., & Pflugfelder, S. C. (2010). Minimal clinically important difference for the ocular surface disease index. *Archives of Ophthalmology*, 128(1), 94–101. <https://doi.org/10.1001/archophthalmol.2009.356>
- Nichols, K. K., Foulks, G. N., Bron, A. J., & Sullivan, D. A. (n.d.). *Meibomian gland dysfunction: What is it, why does it occur and how may it be treated?* (Report). https://www.tearfilm.org/pdfs/TFOS_Mgd_Report_Overview.pdf
- Paulsen, A. J., Cruickshanks, K. J., Fischer, M. E., Huang, G.-H., Klein, B. E. K., Klein, R., & Dalton, D. S. (2014). Dry eye in the Beaver Dam offspring study: Prevalence, risk factors, and health-related quality of life. *American Journal of Ophthalmology*, 157(4), 799–806. <https://doi.org/https://doi.org/10.1016/j.ajo.2013.12.023>
- Schiffman, R. M., Christianson, M. D., Jacobsen, G., Hirsch, J. D., & Reis, B. L. (2000). Reliability and validity of the Ocular Surface Disease Index. *Archives of Ophthalmology*, 118(5), 615–21. <https://doi.org/10.1001/archophth.118.5.615>
- Stapleton, F., Alves, M., Bunya, V. Y., Jalbert, I., Lekhanont, K., Malet, F., Na, K. S., Schaumberg, D., Uchino, M., Vehof, J., Viso, E., Vitale, S., & Jones, L. (2017). TFOS DEWS II Epidemiology report. *The Ocular Surface*, 15(3), 334–365. <https://doi.org/10.1016/j.jtos.2017.05.003>
- The Epidemiology of Dry Eye Disease: Report of the Epidemiology Subcommittee of the International Dry Eye Workshop. (2007). *The Ocular Surface*, 5(2), 93–107. [https://doi.org/https://doi.org/10.1016/S1542-0124\(12\)70082-4](https://doi.org/https://doi.org/10.1016/S1542-0124(12)70082-4)
- Tomlinson, A., Bron, A. J., Korb, D. R., Amamo, S., Paugh, J. R., Pearce, E. I., Yee, R., Yokoi, N., Arita, R., & Dogru, M. (2011). The international workshop on meibomian gland dysfunction: Report of the diagnosis subcommittee. *Investigative Ophthalmology & Visual Science*, 52(4), 2006–49. <https://doi.org/10.1167/iovs.10-6997f>
- Uchino, M., Dogru, M., Yagi, Y., Goto, E., Tomita, M., Kon, T., Saiki, M., Matsumoto, Y., Uchino, Y., Yokoi, N., Kinoshita, S., & Tsubota, K. (2006). The features of dry eye disease in a Japanese elderly population. *Optometry and Vision Science*, 83(11), 797–802. <https://doi.org/10.1097/O1.opx.0000232814.39651.1a>
- Uchino, M., Uchino, Y., Dogru, M., Kawashima, M., Yokoi, N., Komuro, A., Sonomura, Y., Kato, H., Kinoshita, S., Schaumberg, D. A., & Tsubota, K. (2014). Dry eye disease and work productivity loss in visual display users: The Osaka study. *American Journal of Ophthalmology*, 157(2), 294–300. <https://doi.org/10.1016/j.ajo.2013.10.014>
- van Tilborg, M. M., Murphy, P. J., & Evans, K. S. (2015). Agreement in dry eye management between optometrists and general practitioners in primary health care in the Netherlands. *Contact Lens and Anterior Eye*, 38(4), 283–93. <https://doi.org/10.1016/j.clae.2015.03.005>
- Viso, E., Gude, F., & Rodríguez-Ares, M. T. (2011). The association of meibomian gland dysfunction and other common ocular diseases with dry eye: A population-based study in Spain. *Cornea*, 30(1), 1–6. <https://doi.org/10.1097/ICO.0b013e3181da5778>
- Wan, K. H., Chen, L. J., & Young, A. L. (2016). Depression and anxiety in dry eye disease: A systematic review and meta-analysis. *Eye (Lond)*, 30(12), 1558–1567. <https://doi.org/10.1038/eye.2016.186>
- Willcox, M. D. P., Argueso, P., Georgiev, G. A., Holopainen, J. M., Laurie, G. W., Millar, T. J., Papas, E. B., Rolland, J. P., Schmidt, T. A., Stahl, U., Suarez, T., Subbaraman, L. N., Ucakhan, O. O., & Jones, L. (2017). TFOS DEWS II Tear film report. *The Ocular Surface*, 15(3), 366–403. <https://doi.org/10.1016/j.jtos.2017.03.006>
- Wolffsohn, J. S., Arita, R., Chalmers, R., Djalilian, A., Dogru, M., Dumbleton, K., Gupta, P. K., Karpecki, P., Lazreg, S., Pult, H., Sullivan, B. D., Tomlinson, A., Tong, L., Villani, E., Yoon, K. C., Jones, L., & Craig, J. P. (2017). TFOS DEWS II Diagnostic methodology report. *The Ocular Surface*, 15(3), 539–574. <https://doi.org/10.1016/j.jtos.2017.05.001>
- Xiao, J., Adil, M. Y., Chen, X., Utheim Ø, A., Røeder, S., Tonseth, K. A., Lagali, N. S., Dartt, D. A., & Utheim, T. P. (2020). Functional and morphological evaluation of meibomian glands in the assessment of meibomian gland dysfunction subtype and severity. *American Journal of Ophthalmology*, 209, 160–167. <https://doi.org/10.1016/j.ajo.2019.09.005>

Avdekking av tørre øyne i norsk optometrisk praksis: en tverrsnittstudie

Sammendrag

Optikere er en del av primærhelsetjenesten, og det er viktig at de hensiktsmessig diagnostiserer pasienter som kan ha nytte av behandling av tørre øyne. Målet med studien var å utforske hvordan tørre øyne kan avdekkes i optometrisk praksis.

En tverrsnittstudie, som undersøkte symptomer og tegn på tørre øyne blant 186 pasienter (18-70 år) ved rutinemessig synsundersøkelse. Tørre øye ble definert i henhold til kriteriene i «Tear Film and Ocular Surface Society Dry Eye Workshop II». Standard statistiske tester ble benyttet, og diagnostisk kvalitet ble vurdert ved analyse av sensitivitet, spesifisitet og ROC-kurveanalyse.

Femtiseks pasienter brukte kontaktlinser. De var signifikant yngre enn de som ikke brukte kontaktlinser (gjennomsnittsalder 35 ($SD = 1$) mot 48 (± 2) år). Gjennomsnittlig beste korrigerte visus (BCVA) på det beste øyet var 1.0 (± 0.1) (desimalvisus). Det var ingen forskjell i BCVA mellom kontaktlinsebrukere og ikke-kontaktlinsebrukere. Gjennomsnittlig Ocular Surface Disease Index (OSDI) score var 22 (± 19) og 138 pasienter hadde minst en positiv homeostasemarkør for tørt øye. Åttiseks pasienter hadde tørre øyne, 52 hadde tegn uten symptomer, og 23 hadde symptomer uten tegn på tørre øyne. OSDI hadde en sensitivitet og spesifisitet på henholdsvis 62% og 54% for å avdekke homeostasemarkører for tørre øyne. I alt hadde 106 pasienter meibomsk kjerteldysfunksjon (MGD), hvorav 49 var asymptotiske. ROC-kurveanalyse viste at en OSDI-score ≥ 13 kan skille mellom pasienter med fluorescein "break-up-time" (FBUT) < 10 sekunder og en FBUT ≥ 10 sekunder, men ikke mellom pasienter med og uten staining eller MGD.

Flertallet av pasientene som kom til rutinemessig synsundersøkelse hadde tegn og/eller symptomer på tørre øyne. Rutinemessig undersøkelse av FBUT og meibomske kjertler kan gjøre det mulig å avdekke tørre øyne i optometrisk praksis.

Nøkkelord: tørre øyne, Ocular Surface Disease Index, meibomsk kjerteldysfunksjon, fluorescein break-up time, punktat fargeopptak, staining

Ricerca sui casi di occhio secco in una clinica optometrica norvegese: uno studio trasversale

Riassunto

Gli optometristi sono i primi a fornire trattamento per la salute oculare ed è essenziale che identifichino efficientemente i pazienti che possono beneficiare dal trattamento di occhio secco. Lo scopo di questo studio è di esplorare i risultati di una ricerca sulla malattia dell'occhio secco in una clinica optometrica.

Uno studio trasversale ha esaminato sintomi e segni di 186 pazienti (18 a 70 anni) i quali sono stati sottoposti a una visita dell'occhio di routine con l'occhio secco definito secondo i criteri del Tear Film and Ocular Surface Society Dry Eye Workshop II. Test statistici standard sono stati utilizzati e test clinici diagnostici considerando sensibilità, specificità e la curva statistica ROC.

Cinquantasei pazienti erano portatori di lenti a contatto e significativamente più giovani che i non-portatori con un'età di 35 ($SD = 1$) contro 48 (± 2) anni. La media della miglior acuità visiva corretta (BCVA) nell'occhio migliore era 1.0 (± 0.1) (acuità decimale). Non c'è stata differenza statisticamente significativa in BCVA tra portatori e non portatori di lenti a contatto. La media (SD) del punteggio dell'Ocular Surface Disease Index (OSDI) è stato 22 (± 19), e 138 pazienti ha avuto almeno un marcatore dell'omeostasi positivo. A 86 pazienti è stato diagnosticato l'occhio secco, 52 hanno avuto segni senza sintomi e 23 hanno avuto sintomi senza segni di occhio secco. La sensibilità e specificità dell'OSDI in differenziare qualsiasi marcatore di omeostasi furono 62% e 54% rispettivamente. 106 pazienti sono stati diagnosticati con disfunzione delle ghiandole di meibomio (MGD), di cui 49 furono asintomatici. Nell'analisi ROC, l'OSDI ≥ 13 ha dimostrato una abilità diagnostic per differenziare tra soggetti con tempo di rottura lacrimale effettuato con fluoresceina (FBUT) < 10 secondi e FBUT ≥ 10 secondi, ma non tra pazienti con e senza colorazione con fluoresceina o MGD.

La maggior parte dei pazienti considerati ha avuto segni o sintomi da occhio secco. La valutazione di routine di FBUT e delle ghiandole di meibomio possono aiutare a scoprire casi di occhio secco nella clinica optometrica.

Parole chiave: malattia dell'occhio secco, Ocular Surface Disease Index, disfunzione delle ghiandole di meibomio, tempo di rottura lacrimale, colorazioni oculari